查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649463

表觀遺傳學藥物和診斷市場 - 預測 2025 年至 2030 年

Epigenetics Drugs and Diagnostic Technologies Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

表觀遺傳藥物和診斷市場預計將以 15.21% 的複合年成長率成長，從 2025 年的 262.83 億美元成長至 2030 年的 533.45 億美元。

表觀遺傳診斷研究在不改變 DNA 序列本身的情況下遺傳、細胞和身體特徵的變化。該領域是各種變化的指標，在發育生物學中發揮重要作用。表觀遺傳藥物和診斷技術市場的發展受到糖尿病和肥胖等疾病發病率上升的推動，這些疾病與發炎、代謝、心血管和腫瘤疾病有關。此外，表觀遺傳學與精神健康狀況的診斷越來越相關。由於基因表現對行為有深遠的影響，科學家可以探索神經遺傳學如何受到環境因素的影響。這項研究可以幫助我們更好地理解成癮和憂鬱症等問題。人們對個人基因組學的興趣日益濃厚，使得收集個人表觀遺傳資料和核酸定序變得更加容易，使消費者更容易獲得個人化醫療。隨著 DNA資料的成長，表觀遺傳檢測將能夠支持研究並透過個人化醫療方法提供價值。

表觀遺傳藥物與診斷市場促進因素：

  • 癌症患者數量的增加：全球癌症患者數量的增加是推動表觀遺傳藥物和診斷技術市場成長的主要因素。根據美國癌症協會（ACS）預測，2022年全球將有2,020萬癌症新病例和970萬癌症死亡病例，其中乳癌、肺癌、攝護腺癌、大腸直腸癌和胃癌佔比接近50%。

研究表明，癌症進展通常與表觀遺傳異常和基因變化有關。癌症研究表觀遺傳學的進展集中在 DNA 甲基化、組蛋白修飾、核小體定位和非編碼 RNA（如微型RNA表達）等領域。因此，表觀遺傳治療應運而生。例如，Galleri 測試等測試透過識別癌症特異性的甲基化模式來提高診斷能力，將篩檢從常規篩檢擴展到胰腺癌和卵巢癌等癌症。

影響表觀遺傳藥物和診斷市場的地理趨勢：

  • 亞太地區快速成長：表觀遺傳藥物和診斷技術市場分為北美、南美、歐洲、中東和非洲以及亞太地區。在預測期內，由於中國、日本、印度和韓國等新興經濟體數量不斷增加，推動醫療保健基礎設施的發展，亞太地區預計將成為該市場成長最快的地區。

例如，2022年中國將報告約482萬例新發癌症病例和257萬例癌症死亡病例。該地區慢性病患病率的不斷上升預計將推動對錶觀遺傳學相關的先進診斷技術的需求。另一方面，北美憑藉其先進的醫療保健基礎設施預計將佔據市場的大部分佔有率。神經系統疾病的高發生率也助長了這種成長。預測表明，未來幾年阿茲海默症症等疾病將影響數百萬人。摘要，表觀遺傳藥物和診斷市場將迎來顯著成長，這得益於全球癌症發病率的上升、人們對早期診斷選擇的認知的不斷提高、表觀遺傳研究和技術的進步、政府在醫療保健投資方面的支持性舉措以及特別是亞太地區的有利區域趨勢，這些都加強了這一不斷擴大的市場環境。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛用戶：對於新興企業、科學研究機構、顧問公司、中小企業和大型企業來說都是有益且具成本效益的。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的歷史資料與預測
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測分析包括國家在內的細分市場和地區
  • 公司概況（尤其是主要趨勢）

表觀遺傳藥物和診斷市場細分如下：

按藥物

  • 組蛋白去乙醯化酶 (HDAC) 抑制劑
  • DNA甲基轉移酵素(DNMT) 抑制劑
  • 其他

依技術分類

  • 試劑
  • 套件
  • 晶片定序試劑套件
  • 全基因組擴增試劑套件
  • 亞硫酸鹽轉化試​​劑套件
  • RNA定序套件
  • 裝置
  • 服務
  • 其他

按應用

  • 腫瘤疾病
  • 非腫瘤疾病
  • 發炎性疾病
  • 代謝紊亂
  • 傳染病
  • 心血管疾病
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
  • 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 其他中東和非洲地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他亞太地區

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程
  • 資料檢驗

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

第 5 章表觀遺傳藥物和診斷市場（按藥物）

  • 介紹
  • 組蛋白去乙醯化酶 (HDAC) 抑制劑
  • DNA甲基轉移酵素(DNMT) 抑制劑
  • 其他

6. 表觀遺傳藥物和診斷市場（按技術）

  • 介紹
  • 試劑
  • 套件
    • 晶片定序試劑套件
    • 全基因組擴增試劑套件
    • 亞硫酸鹽轉化試​​劑套件
    • RNA定序套件
  • 裝置
  • 服務
  • 其他

第7章表觀遺傳學藥物和診斷市場（按應用）

  • 介紹
  • 腫瘤疾病
  • 非腫瘤疾病
    • 發炎性疾病
    • 代謝紊亂
    • 感染疾病
    • 心血管疾病
    • 其他

8. 表觀遺傳藥物和診斷市場（按地區）

  • 世界概況
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他亞太地區

第9章競爭格局及分析

  • 主要企業和策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Element Biosciences, Inc.
  • Dovetail Genomics LLC.
  • Abcam plc.
  • Eisai Co., Ltd.
  • Novartis AG
  • Cantata Bio
  • Illumina, Inc.
  • Promega Corporation
  • Merck KGaA
簡介目錄
Product Code: KSI061617239

The epigenetics drugs and diagnostic technologies market is expected to grow at a CAGR of 15.21%, reaching a market size of US$53.345 billion in 2030 from US$26.283 billion in 2025.

Epigenetics diagnosis involves studying changes in genetic, cellular, and physical characteristics without altering the DNA sequence itself. This field serves as an indicator of various changes and plays a vital role in developmental biology. The market for epigenetics drugs and diagnostic technologies is driven by the rising incidence of disorders such as diabetes and obesity, which are linked to inflammatory, metabolic, cardiovascular, and oncological diseases.Moreover, epigenetics is increasingly relevant in diagnosing mental health conditions. Gene expression significantly influences behavior, allowing scientists to explore neurogenetics shaped by environmental factors. This research can enhance understanding of issues like addiction and depression. The growing interest in personal genomics facilitates the collection of individual epigenetic data and DNA sequencing, making personalized medicine more attainable for consumers. As data on DNA increases, epigenetic testing becomes more capable of supporting research and delivering value through tailored medical approaches.

Drivers of the Epigenetics Drugs and Diagnostic Technologies Market:

  • Rising Incidence of Cancer Cases: The global increase in cancer cases is a major factor propelling growth in the epigenetics drugs and diagnostic technologies market. According to the American Cancer Society (ACS), there were 20.2 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with prevalent cancers including breast, lung, prostate, colorectal, and stomach cancers-accounting for nearly 50% of total cases.

Research has shown that cancer progression is often associated with epigenetic abnormalities alongside genetic changes. Epigenetic advancements in cancer research focus on areas such as DNA methylation, histone modifications, nucleosome positioning, and non-coding RNAs like microRNA expression. This has led to the emergence of epigenetic therapies. For example, tests like the Galleri test improve diagnostic capabilities by identifying cancer-specific methylation patterns and extending screening beyond routine methods to include cancers such as pancreatic and ovarian cancer.

Geographical Trends Shaping the Epigenetics Drugs and Diagnostic Technologies Market:

  • Rapid Growth in Asia-Pacific: The epigenetics drugs and diagnostic technologies market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is expected to be the fastest-growing region in this market due to emerging economies like China, Japan, India, and South Korea driving healthcare infrastructure development.

For instance, approximately 4.82 million new cancer cases and 2.57 million cancer deaths were reported in China in 2022. The increasing prevalence of chronic diseases in this region is expected to propel demand for advanced diagnostic technologies related to epigenetics.Meanwhile, North America is projected to maintain a significant share of the market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this growth; projections indicate that there will be millions affected by conditions like Alzheimer's disease in the coming years. Furthermore, substantial government investments alongside private sector initiatives are expected to drive continued regional expansion.In summary, the epigenetics drugs and diagnostic technologies market is poised for significant growth driven by rising cancer incidence rates globally, increasing awareness about early diagnosis options, advancements in epigenetic research and technology, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Epigenetics Drugs And Diagnostic Technologies Market has been segmented as following:

By Drugs

  • Histone Deacetylase (HDAC) Inhibitors
  • DNA Methyltransferase (DNMT) Inhibitors
  • Others

By Technology

  • Reagents
  • Kits
  • Chip Sequencing Kit
  • Whole Genomic Amplification Kit
  • Bisulfite Conversion Kit
  • RNA Sequencing Kit
  • Instruments
  • Services
  • Others

By Application

  • Oncology
  • Non-oncology
  • Inflammatory Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY DRUGS

  • 5.1. Introduction
  • 5.2. Histone Deacetylase (HDAC) Inhibitors
  • 5.3. DNA Methyltransferase (DNMT) Inhibitors
  • 5.4. Others

6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Reagents
  • 6.3. Kits
    • 6.3.1. Chip Sequencing Kit
    • 6.3.2. Whole Genomic Amplification Kit
    • 6.3.3. Bisulfite Conversion Kit
    • 6.3.4. RNA Sequencing Kit
  • 6.4. Instruments
  • 6.5. Services
  • 6.6. Others

7. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Non-oncology
    • 7.3.1. Inflammatory Diseases
    • 7.3.2. Metabolic Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Cardiovascular Diseases
    • 7.3.5. Others

8. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY GEOGRAPHY

  • 8.1. Global Overview
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Rest of South America
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Rest of Europe
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. United Arab Emirates
    • 8.5.3. Rest of the Middle East and Africa
  • 8.6. Asia-Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Rest of Asia-Pacific

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Roche Diagnostics
  • 10.2. Thermo Fisher Scientific, Inc.
  • 10.3. Element Biosciences, Inc.
  • 10.4. Dovetail Genomics LLC.
  • 10.5. Abcam plc.
  • 10.6. Eisai Co., Ltd.
  • 10.7. Novartis AG
  • 10.8. Cantata Bio
  • 10.9. Illumina, Inc.
  • 10.10. Promega Corporation
  • 10.11. Merck KGaA